Tag Archives: NASDAQ:ANTH

Anthera Pharmaceuticals (NASDAQ:ANTH) Net Loss Narrows in Fiscal Fourth Quarter

Posted on March 27, 2013 by Thomas Vedder

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) announced on Thursday that net loss in fiscal fourth-quarter was $8.9 million or $0.11 a share, narrower than $29.2 million or $0.71 a share in the similar period a year ago.

Thomson Reuters 7 analysts’ survey …

Posted in Healthcare, Main Post | Tagged ANTH, Anthera Pharmaceuticals, Eli Lilly, IMMU, Immunomedics, LLY, Merck, MRK, NASDAQ:ANTH, NASDAQ:IMMU, NYSE:LLY, NYSE:MRK | Comments Off

Humana Inc.’s (NYSE:HUM) Profit Slips on Inflated Coverage Costs – HUM, LLY, ANTH, RMTI, CTIC, ARNA, LLY,

Posted on February 4, 2013 by Thomas Vedder

Humana Inc.’s (NYSE:HUM) fourth-quarter earnings plunged down 3.5% as inflated coverage costs covered the health-care firm’s revenue growth from hiked membership. Past month, Humana finished its approximately $850 million takeover of Metropolitan Health Networks Inc., a medical-services supplier mainly operating …

Posted in Healthcare, Latest Headlines | Tagged ANTH, Anthera Pharmaceuticals, Arena Pharmaceuticals, ARNA, Cell Therapeutics, CTIC, Eli Lilly, HUM, Humana, LLY, NASDAQ:ANTH, NASDAQ:ARNA, NASDAQ:CTIC, NASDAQ:RMTI, NYSE:HUM, NYSE:LLY, RMTI, Rockwell Medical | Comments Off

Morgan Stanley (MS) Shatter Merck (NYSE:MRK) Stock Rating after Quarterly Results – MRK, GALE, TEVA, ANTH, JNJ, HEB, BMY, GSK, NVS

Posted on February 4, 2013 by Geoff Noir

Merck & Co., Inc (NYSE:MRK) stock rationing was lower to market perform by Lee rink Swann while Morgan Stanley shatters their rationing to underweight.

Shares of second biggest drug maker in US plunged on Monday in early trading session as …

Posted in Healthcare, Latest Headlines | Tagged ANTH, Anthera Pharmaceuticals, BMY, Bristol-Myers Squibb, GALE, Galena Biopharma, GlaxoSmithKline, GSK, HEB, Hemispherx BioPharma, JNJ, Johnson & Johnson, Merck, MRK, NASDAQ:ANTH, NASDAQ:GALE, Novartis, NVS, NYSE:BMY, NYSE:GSK, NYSE:JNJ, NYSE:MRK, NYSE:NVS, NYSE:TEVA, NYSEAMEX:HEB, TEVA, Teva Pharmaceutical Industries | Comments Off

Covidien PLC (NYSE:COV) Superior Sales Masked by Split Off Costs, Outlook Raised – COV, BDX, BCR, BMY, PFE, JNJ, ANTH, ABT, KERX

Posted on January 25, 2013 by Thomas Vedder

Covidien PLC (NYSE:COV) witnessed a 0.2% drop in fiscal first-quarter earnings as costs to divide the health-care products firm weighed over its bubbly sales.

The firm also lifted its fiscal 2013 sales target, now anticipating a 5% to 8% hike, …

Posted in Healthcare, Latest Headlines | Tagged Abbott Laboratories, ABT, ANTH, Anthera Pharmaceuticals, BCR, BDX, Becton, BMY, Bristol-Myers Squibb, C.R. Bard, COV, Covidien, Dickinson, JNJ, Johnson & Johnson, KERX, Keryx Biopharmaceuticals, NASDAQ:ANTH, NASDAQ:KERX, NYSE:ABT, NYSE:BCR, NYSE:BDX, NYSE:BMY, NYSE:COV, NYSE:JNJ, NYSE:PFE, PFE, Pfizer | Comments Off

Amarin Corp. (NASDAQ:AMRN)Risks with Vascepa Launch Plunges Stock – AMRN, MRK, PDLI, PPHM, ANTH, BMY, ARNA, CHTP

Posted on December 7, 2012 by Thomas Vedder

Shares of Amarin Corp. (NASDAQ:AMRN)plunged 17% to $9.87 per share in early trading hours on Friday following the drug manufacturer took out a credit line of $100 million as it sets up for the release of its Vascepa drug to …

Posted in Healthcare, Latest Headlines | Tagged Amarin, AMRN, ANTH, Anthera, arena, ARNA, BMY, Bristol-Myers Squibb, Chelsea Therapeutics, CHTP, Merck, MRK, NASDAQ:AMRN, NASDAQ:ANTH, NASDAQ:ARNA, NASDAQ:CHTP, NASDAQ:PDLI, NASDAQ:PPHM, NYSE:BMY, NYSE:MRK, PDL BioPharma, PDLI, Peregrine, PPHM | Comments Off

Johnson & Johnson (JNJ) Lowers 2012 Guidance; Profit Smashed by Currency Rates

Posted on July 17, 2012 by Thomas Vedder

Johnson & Johnson (NYSE:JNJ), the world’s largest manufacturer of health-care items, trimmed its full-year profit estimation on critical foreign-exchange rates.

J&J’s 2Q net income declined almost 49 percent to $1.4 billion, or 50 cents per share, on takeover expense, …

Posted in Healthcare, Latest Headlines | Tagged Anthera, Arena Pharmaceuticals, Covidien, JNJ, Johnson & Johnson, NASDAQ:ANTH, NASDAQ:ARNA, NASDAQ:OREX, NASDAQ:SLTM, NASDAQ:STEM, NASDAQ:VVUS, Novartis AG, NYSE:COV, NYSE:JNJ, NYSE:NVS, Orexigen Therapeutics, Solta Medical, StemCells, Vivus | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.